Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- ESSA Pharmaceuticals
- Target Recruit Count
- 99
- Registration Number
- NCT04421222
- Locations
- 🇺🇸
Hematology Oncology Associates of the Treasure Coast, Port St. Lucie, Florida, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2022-12-16
- Target Recruit Count
- 75
- Registration Number
- NCT04356430
- Locations
- 🇨🇳
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, China
Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone
- Conditions
- Interventions
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Stanford University
- Registration Number
- NCT04296578
A Study Designed to Evaluate the Pharmacokinetic Profile of Abiraterone
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Zentiva, k.s.
- Target Recruit Count
- 33
- Registration Number
- NCT04295161
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, United Kingdom
PK and Dose Escalation and Expansion Study of DST-2970
- Conditions
- Interventions
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- DisperSol Technologies, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT04291664
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 7
- Registration Number
- NCT04267887
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT04262154
- Locations
- 🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Commack (Limited Protocol Activities), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 461
- Registration Number
- NCT04221542
- Locations
- 🇺🇸
Sanford Oncology Clinic and Pharmacy, Sioux Falls, South Dakota, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Providence Saint Jude Medical Center, Fullerton, California, United States
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
- Conditions
- Interventions
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 67
- Registration Number
- NCT04207255
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Emory University, Atlanta, Georgia, United States
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT04194554
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Cornell University, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.